TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Adherium Ltd. ( (AU:ADR) ) has shared an announcement.
Adherium Limited has announced a partnership with Allergy Partners to deploy its Hailie® Smartinhaler® technology across more than 100 clinics. This collaboration aims to enhance respiratory care on a large scale in the US and potentially beyond, showcasing Adherium’s commitment to improving healthcare outcomes through digital solutions.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices. The company has sold over 180,000 devices globally and offers the Hailie® platform, which allows clinicians, healthcare providers, and patients to remotely monitor medication usage and adherence. The platform includes integration tools for capturing and sharing health data, designed to provide healthcare providers with insights into medication use patterns in respiratory disease management.
Technical Sentiment Signal: Sell
Current Market Cap: A$9.97M
Learn more about ADR stock on TipRanks’ Stock Analysis page.